ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 171 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2019. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $27,338,000 | -16.3% | 430,627 | -8.5% | 0.37% | -15.2% |
| Q1 2019 | $32,654,000 | +63.0% | 470,847 | +2.2% | 0.43% | +36.1% |
| Q4 2018 | $20,038,000 | -44.0% | 460,852 | -1.7% | 0.32% | -34.0% |
| Q3 2018 | $35,775,000 | +1.0% | 468,631 | +1.7% | 0.48% | -4.2% |
| Q2 2018 | $35,410,000 | +40.0% | 460,648 | -7.1% | 0.50% | +41.6% |
| Q1 2018 | $25,286,000 | +5.6% | 495,893 | -3.9% | 0.36% | +5.0% |
| Q4 2017 | $23,937,000 | -13.7% | 516,113 | -0.9% | 0.34% | -29.8% |
| Q3 2017 | $27,750,000 | -12.8% | 521,035 | +1.7% | 0.48% | -17.3% |
| Q2 2017 | $31,827,000 | -24.8% | 512,430 | -17.9% | 0.58% | +84.8% |
| Q1 2017 | $42,307,000 | +5.5% | 624,174 | +9.4% | 0.32% | +0.6% |
| Q4 2016 | $40,099,000 | +14.7% | 570,321 | +15.7% | 0.31% | +18.9% |
| Q3 2016 | $34,966,000 | – | 492,900 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 497,899 | $31,617,000 | 3.20% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 390,453 | $24,794,000 | 1.81% |
| First Light Asset Management, LLC | 180,017 | $11,431,000 | 1.59% |
| Rock Springs Capital Management LP | 580,000 | $36,830,000 | 1.33% |
| Capital Impact Advisors, LLC | 36,165 | $2,244,000 | 0.82% |
| SECTOR GAMMA AS | 79,653 | $5,058,000 | 0.81% |
| Verity Asset Management, Inc. | 7,193 | $457,000 | 0.51% |
| Opus Point Partners Management, LLC | 5,064 | $322,000 | 0.48% |
| Capital International Sarl | 52,000 | $3,302,000 | 0.46% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 6,216 | $394,000 | 0.43% |